C4 Therapeutics, Inc.
CCCCBusiness Summary
C4 Therapeutics, Inc. (the "Company") is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD) to develop small-molecule medicines. The company leverages its proprietary TORPEDO platform to design and optimize these degraders, aiming for best-in-class or first-in-class potential in areas of unmet patient need. Their strategy involves developing degraders that modulate clinically validated disease pathways, with a current focus on oncology, inflammation, neuroinflammation, and neurodegeneration. The company has demonstrated oral bioavailability and catalytic activity in its degraders, and has also developed compounds that are brain penetrant 1.
The company's core business model revolves around the discovery, development, and potential commercialization of novel therapies using its TORPEDO platform. Revenue is primarily generated through research collaboration and license agreements, with no product sales revenue to date 2. The company aims to address significant unmet patient needs by developing degraders that offer advantages over traditional inhibitors, such as improved and sustained potency, high selectivity, and an expansive target landscape, including previously "undruggable" targets 3.
C4 Therapeutics' clinical pipeline includes two oncology degraders. Cemsidomide is an orally bioavailable MonoDAC (molecular glue type) degrader targeting IKZF1 and IKZF3 (IKZF1/3) for multiple myeloma (MM) 4. It is currently in a Phase 2 trial in combination with dexamethasone, and a Phase 1b trial in combination with elranatamab, supplied by Pfizer Inc. 5. The Phase 1 trial demonstrated a differentiated safety profile and compelling anti-myeloma activity 6. The annual MM prevalence in the fourth-line setting was approximately 42,000 patients in the United States, United Kingdom, Germany, Italy, France, and Spain in 2024 7. The Phase 2 MOMENTUM trial aims to enroll approximately 100 patients, with full enrollment expected in Q1 2027 8.
The second clinical-stage oncology product candidate is CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR) with an L858R mutation for non-small-cell lung cancer (NSCLC) 9. CFT8919 is being clinically developed in Greater China by collaboration partner Betta Pharma, which dosed the first patient in a Phase 1 clinical trial in November 2024 10. The company retains all rights to develop and commercialize CFT8919 outside of Greater China 11. In 2024, approximately 419,380 patients in the United States, United Kingdom, and EU4 combined were diagnosed with NSCLC, with 10-15% having mutant EGFR 12. In China, approximately 45,780 patients are diagnosed with NSCLC annually, with about 50% driven by the EGFR mutation 13.
The company reported total revenue from collaboration agreements of $35.947 million for the year ended December 31, 2025, a slight increase from $35.584 million in 2024 14. Research and development expenses decreased to $104.240 million in 2025 from $110.637 million in 2024 15. General and administrative expenses also decreased to $36.196 million in 2025 from $42.124 million in 2024 16. The net loss for 2025 was $105.0 million, compared to $105.3 million in 2024 17. As of December 31, 2025, the company had cash, cash equivalents, and marketable securities of approximately $297.1 million 18.
The year-over-year revenue increase of $0.4 million was primarily driven by an $11.2 million increase from the Merck KGaA collaboration due to the prioritization of a KRAS project, a $4.8 million increase from the Roche collaboration as two active programs progressed to the lead series identification achievement phase and a milestone was earned for each, and a $2.0 million increase from a former Merck agreement upon termination notice 19. These gains were partially offset by a $14.9 million decrease from the Biogen collaboration, as active research concluded in March 2024 and only one $2.0 million milestone was recognized in 2025 compared to $16.0 million in 2024, and a $2.9 million decrease from the Betta Pharma collaboration due to higher program activity in the prior year 20. The decrease in R&D expenses was mainly due to a $4.1 million decrease in preclinical development and discovery expenses, a $1.6 million decrease in personnel expenses, a $1.4 million decrease in professional fees, and a $1.3 million decrease in clinical expenses following the completion of the Phase 1 trial of CFT1946 21. This was partially offset by a $1.9 million increase in facilities and supplies due to the end of a sublease agreement in June 2025 22.
Significant operational developments during the period include the dosing of the first patient in the Phase 2 MOMENTUM trial for cemsidomide in February 2026 23. In October 2025, the company entered into a supply agreement with Pfizer for elranatamab for the Phase 1b trial of cemsidomide 24. In October 2025, the company raised $125 million in gross proceeds through an underwritten offering, with potential for an additional $225 million if outstanding warrants are exercised 25. A $1.0 million discovery milestone was achieved for one of the Merck KGaA collaboration targets in April 2025 26. In March 2025, a $2.0 million milestone was achieved for each of the two active Roche collaboration targets upon progression to the lead series identification achievement phase 27. In September 2025, the company received a $2.0 million milestone from Biogen after BIIB142, an IRAK4 degrader, advanced into the clinic 28. In January 2026, a second $2.0 million milestone was earned from Biogen after BIIB129, a BTK degrader, advanced into Phase 1 clinical development 29.
Business Outlook
The company believes that its existing cash, cash equivalents, and marketable securities of approximately $297.1 million as of December 31, 2025, combined with the net proceeds of approximately $116.9 million from the October 2025 underwritten offering, will be sufficient to fund its planned operating expenses until the end of 2028 30. This estimate does not include any anticipated proceeds from the potential exercise of the Pre-Funded Warrants, Class A Warrants, or Class B Warrants issued in the 2025 Offering 31. The company's future capital requirements are dependent on factors such as the timing and costs of clinical trials, the number of product candidates pursued, the success of collaborations, regulatory review outcomes, and commercialization expenses 32.
A major growth area for the company is the advancement of its clinical oral oncology degrader programs. Cemsidomide, an IKZF1/3 degrader for multiple myeloma, is progressing to later-stage studies with an efficient regulatory strategy that includes the potential for two accelerated approvals 33. The Phase 2 MOMENTUM clinical trial for cemsidomide in combination with dexamethasone for MM patients who have had at least three prior lines of therapy began enrolling patients in February 2026, with full trial enrollment expected in Q1 2027 34. This trial has the potential for accelerated approval in the later-line MM setting 35. Additionally, cemsidomide is being evaluated in a Phase 1b clinical trial in combination with elranatamab, a BCMAxCD3 Bispecific, in earlier lines of MM therapy, aiming to enhance depth of response while maintaining a manageable safety profile 36.
Another key growth area is the progression of a new internal discovery strategy focused on inflammation, neuroinflammation, and neurodegeneration 37. The company is selecting targets where targeted protein degradation (TPD) offers a clear and compelling advantage over other therapeutic options, including developing degraders that are central nervous system (CNS) penetrant 38. They have extended capabilities to identify molecular glue degraders for targets with and without G- and RT-loops by utilizing DNA-encoded library (DEL) technology and enhancements to their TORPEDO platform, advancing programs to lead optimization and development candidate nominations 39. The company believes degraders have the potential to deliver the efficacy of a biologic in the CNS where biologics are not effective, and to outperform small molecule inhibitors in efficacy and safety in CNS diseases due to lower exposure requirements and extended PKPD 40.
Operationally, the company expects its research and development expenses to continue to increase substantially as it advances preclinical and clinical development activities, expands its proprietary research and development portfolios, and invests in its TORPEDO platform 41. General and administrative expenses are also expected to increase to support these expanded activities, including hiring additional personnel and incurring fees for outside consultants, lawyers, and accountants 42. The company's facilities and supplies expenses increased by $1.9 million in 2025 due to the end of a sublease agreement in June 2025 43.
Planned capital allocation includes continued investment in the proprietary TORPEDO platform and advancing, expanding, maintaining, and protecting its intellectual property portfolio 44. The company also plans to seek marketing approvals for any product candidates that successfully complete clinical trials and establish a sales, marketing, and distribution infrastructure and scale up external manufacturing capabilities for commercialization 45. The company received net proceeds of approximately $116.9 million from an underwritten offering in October 2025, and $9.3 million from an at-the-market offering in 2025 46. The potential aggregate net proceeds from the 2025 offering, if all warrants are exercised, are expected to be $341.7 million 47.
Risk Factors
The company faces substantial risks, including the inherent uncertainty of targeted protein degradation as a new treatment modality, with very few such product candidates tested in humans and none approved, making it difficult to predict development time, cost, and success 48. The company has incurred significant losses, with a net loss of $105.0 million in 2025 and an accumulated deficit of $738.7 million, and expects to incur further losses for several years, requiring substantial additional funding 49. Clinical trials are lengthy, expensive, and uncertain, with a high risk of failure, and preclinical results may not predict human outcomes, potentially leading to delays, increased costs, or abandonment of product candidates 50. The company relies on third parties for manufacturing and clinical trials, which reduces control and increases risks of delays, insufficient quantities, or non-compliance with regulatory requirements like cGMP and GCP 51. Competition in the biopharmaceutical industry is intense, with many companies developing protein degradation therapies and traditional modalities, often with greater financial resources, potentially leading to competitors commercializing products more successfully or rapidly 52. Intellectual property protection is uncertain, with patents potentially being challenged, narrowed, or invalidated, and the company may need to license third-party intellectual property that may not be available on reasonable terms 53. Regulatory approval is lengthy and unpredictable, with the FDA and foreign authorities having substantial discretion, and approval standards can change, potentially leading to limited indications, costly post-marketing trials, or withdrawal of approval 54. The company is subject to evolving healthcare fraud and abuse laws, false claims laws, and privacy regulations, with non-compliance potentially resulting in substantial penalties, fines, and reputational harm 55. Unfavorable pricing regulations, third-party reimbursement practices, and healthcare reform initiatives, such as the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act of 2025, could significantly impact revenue and commercialization efforts by imposing price controls or reducing reimbursement levels 56.
Management Priorities
Management emphasizes its commitment to delivering on the promise of targeted protein degradation (TPD) science to create a new generation of small-molecule medicines that transform patients' lives, leveraging its proprietary TORPEDO platform to efficiently design and optimize small molecule protein degraders 57. The company's strategic priorities include advancing its clinical oral oncology degrader programs, specifically cemsidomide, which is moving into later-stage studies with an efficient regulatory strategy that includes the potential for two accelerated approvals 58. Management also highlights progressing a new internal discovery strategy focused on inflammation, neuroinflammation, and neurodegeneration, areas where TPD could offer significant patient impact, including developing CNS-penetrant degraders 59. Finally, the company aims to realize the full value of its TORPEDO platform through collaborations with partners like Merck KGaA and Roche, which allow for expanded reach and accelerated research in both oncology and non-oncology indications 60. The company believes that its cash, cash equivalents, and marketable securities of approximately $297.1 million as of December 31, 2025, combined with the net proceeds of approximately $116.9 million from the October 2025 underwritten offering, will be sufficient to fund planned operating expenses until the end of 2028 61.
View Source Annual Report on SEC.gov ↗
References
- [1] Item 1, Business — Overview
- [2] Item 7, MD&A — Revenues
- [3] Item 1, Business — Advantages of Targeted Protein Degradation Over Inhibitors
- [4] Item 1, Business — Our Product Candidates—Highly Potent and Selective Targeted Protein Degraders
- [5] Item 7, MD&A — Overview
- [6] Item 1, Business — Clinical Trials of Cemsidomide in MM
- [7] Item 1, Business — Multiple Myeloma
- [8] Item 1, Business — Clinical Trials of Cemsidomide in MM
- [9] Item 1, Business — Our Product Candidates—Highly Potent and Selective Targeted Protein Degraders
- [10] Item 7, MD&A — Overview
- [11] Item 1, Business — Clinical Trials of CFT8919 in Non-Small Cell Lung Cancer
- [12] Item 1, Business — Non-Small-Cell Lung Cancer
- [13] Item 1, Business — Non-Small-Cell Lung Cancer
- [14] Item 7, MD&A — Revenue
- [15] Item 7, MD&A — Research and Development Expenses
- [16] Item 7, MD&A — General and Administrative Expenses
- [17] Item 1A, Risk Factors — Risks related to our financial position and need for additional capital
- [18] Item 7, MD&A — Liquidity and capital resources
- [19] Item 7, MD&A — Revenue
- [20] Item 7, MD&A — Revenue
- [21] Item 7, MD&A — Research and Development Expenses
- [22] Item 7, MD&A — Research and Development Expenses
- [23] Item 7, MD&A — Recent Developments
- [24] Item 7, MD&A — Recent Developments
- [25] Item 7, MD&A — Recent Developments
- [26] Item 1, Business — Merck KGaA Collaboration and License Agreement
- [27] Item 1, Business — Roche Amended and Restated License Agreement
- [28] Item 1, Business — Biogen Collaborative Research and License Agreement
- [29] Item 1, Business — Biogen Collaborative Research and License Agreement
- [30] Item 1A, Risk Factors — Risks related to our financial position and need for additional capital
- [31] Item 1A, Risk Factors — Risks related to our financial position and need for additional capital
- [32] Item 7, MD&A — Funding requirements
- [33] Item 1, Business — Our Strategy
- [34] Item 1, Business — Clinical Trials of Cemsidomide in MM
- [35] Item 1, Business — Clinical Trials of Cemsidomide in MM
- [36] Item 1, Business — Clinical Trials of Cemsidomide in MM
- [37] Item 1, Business — Our Strategy
- [38] Item 1, Business — Our Discovery Approach & Strategy
- [39] Item 1, Business — Our Discovery Approach & Strategy
- [40] Item 1, Business — Our Discovery Approach & Strategy
- [41] Item 7, MD&A — Funding requirements
- [42] Item 7, MD&A — Funding requirements
- [43] Item 7, MD&A — Research and Development Expenses
- [44] Item 7, MD&A — Funding requirements
- [45] Item 7, MD&A — Funding requirements
- [46] Item 7, MD&A — Financing activities
- [47] Item 7, MD&A — Sources of liquidity
- [48] Item 1A, Risk Factors — Our approach to the discovery and development of product candidates based on our TORPEDO platform for targeted protein degradation is unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products.
- [49] Item 1A, Risk Factors — We are a clinical-stage biopharmaceutical company and have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability.
- [50] Item 1A, Risk Factors — Our preclinical studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates, which would prevent or delay development, regulatory approval, and commercialization.
- [51] Item 1A, Risk Factors — We expect to rely on third parties to conduct our current and future clinical trials and those third parties may not perform satisfactorily, including by failing to meet deadlines for the completion of our clinical trials or failing to comply with contractual obligations, regulatory requirements, or our clinical protocols.
- [52] Item 1A, Risk Factors — Targeted protein degradation is a novel modality that continues to attract substantial interest from existing and emerging biotechnology and pharmaceutical companies. As a result, we face substantial competition, which may result in others discovering, developing or commercializing products for the same indication and/or patient population before or more successfully than we do.
- [53] Item 1A, Risk Factors — If we are unable to obtain and maintain patent protection for our technology, product candidates, and products or if the scope of the patent protection obtained is not sufficiently broad or enforceable, our competitors could develop and commercialize technology, product candidates, and products similar or identical to ours, our ability to successfully commercialize our technology, product candidates, and products may be impaired or we may not be able to compete effectively in our market.
- [54] Item 1A, Risk Factors — Receiving regulatory approval from the FDA and foreign regulatory authorities is lengthy, time-consuming and inherently unpredictable and, if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed.
- [55] Item 1A, Risk Factors — Our relationships with customers, healthcare providers, and third-party payors are or will be subject, directly or indirectly, to foreign, federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply or have not fully complied with these laws, we could face substantial penalties.
- [56] Item 1A, Risk Factors — Even if we or, in the case of CFT8919, Betta Pharma, receive marketing approval of any of our product candidates, our products may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, any of which would impact our business.
- [57] Item 7, MD&A — Overview
- [58] Item 1, Business — Our Strategy
- [59] Item 1, Business — Our Strategy
- [60] Item 1, Business — Our Strategy
- [61] Item 1A, Risk Factors — Risks related to our financial position and need for additional capital
Analysis on 5/20/2026